Our knowledge of the major mechanisms underlying the effect of food on drug absorption allows reliable qualitative prediction based on biopharmaceutical properties...
Modelling and PBPK Simulation in Drug Discovery
Physiologically based pharmacokinetic (PBPK) models are composed of a series of differential equations and have been implemented in a number of commercial...
Calculation of molecular lipophilicity: State-of-the-art and comparison of log P methods on more than 96,000 compounds
We first review the state-of-the-art in development of log P prediction approaches falling in two major categories: substructure-based and property-based methods.
Kerfuffle! (pt 2)
Chapter 2 of 3. Need to catch up? Read the previous post in the series.
Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci
Correctly determined susceptibility breakpoints are important to both the individual patient and to society at large. A previously derived patient population...
Toward an In Vivo Dissolution Methodology: A Comparison of Phosphate and Bicarbonate Buffers
The purpose of this research was to evaluate the difference between the pharmaceutical phosphate buffers and the gastrointestinal bicarbonates in dissolution of ketoprofen and indomethacin...
Simulations Plus Reports First Quarter FY2009 Financial Results
Company Sets New Record for First Quarter: Revenues up 7.5% and Earnings Up Over 28%
Simulations Plus Sets Date for First Quarter Fiscal Year 2008 Earnings Release and Conference Call
Conference Call to be on Thursday, January 15, at 4:15 PM EST
Simulations Plus Releases ClassPharmer™ Version 4.6
New Version Further Improves Powerful Data Mining and Drug Design Capabilities
Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation
The aim of the present study was to use gastrointestinal simulation technology and in vitro-in vivo correlation (IVIVC) as tools to investigate a possible extension of biowaiver criteria...
Analysis of Risk Factors in Human Bioequivalence Study That Incur Bioinequivalence of Oral Drug Products
In the study of human bioequivalence (BE), newly developed oral products sometimes fail to prove BE with a reference product due to the high variability in pharmacokinetic (PK)...
Busting the Black Box Myth: Designing Out Unwanted ADMET Properties with Machine Learning Approaches
Drug design is usually understood as “an inventive process of finding new medications based on the knowledge of the biological target” – according to the...
Omeprazole: Physiologically Based Pharmacokinetic (PBPK) Modeling and Prediction of Drug-Drug Interactions (DDI)
To optimize a PBPK model of omeprazole for prediction of DDIs with respect to polymorphic expression of CYP enzymes. Omeprazole absorption and pharmacokinetics were simulated using GastroPlus™.
Azole Antifungals: Physiologically-Based Pharmacokinetic (PBPK) Modeling and Prediction of Drug-Drug Interactions (DDIs)
Develop PBPK models for azole antifungals for prediction of DDIs. The absorption and pharmacokinetics of azole antifungals were simulated using GastroPlus™. The program's Advanced Compartmental and…
Azole Antifungals: Physiologically-Based Pharmacokinetic (PBPK) Modeling and Prediction of Drug-drug Interactions (DDIs)
Download the poster presented at the Rosenon conference in 2009 on the development of PBPK models for common azole antifungals and DDI predictions
Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints
Potential tigecycline-Enterobacteriaceae susceptibility breakpoints were evaluated using 2 approaches, which differed in the nature of the probabilities assessed by MIC value.
Prediction of drug-drug interaction (DDI) between cilostazol and substrates or inhibitors of CYP 2C19 and 3A4
The aim of this study was to validate the utility of physiologically based pharamcokinetic (PBPK) models fore predictioin of DDI between cilostazol, kectoconazole, omeprazole and quindine.
Understanding the effect of API properties on bioavailability through absorption modeling
Selection of API phase is one of the first decision points in the formulation development process.
Simulations Plus Reports FY2008 Financial Results
Earnings Up 17.7%, Shareholder Equity Up 29.4% Over Previous Fiscal Year
Prediction of Drug Clearance by Glucuronidation from in Vitro Data: Use of Combined Cytochrome P450 and UDP-Glucuronosyltransferase Cofactors in Alamethicin-Activated Human Liver Microsomes
Glucuronidation via UDP-glucuronosyltransferase (UGT) is an increasingly important clearance pathway.